LIR Life Sciences Corp.
BBCMF
$0.07
-$0.18-73.76%
OTC PK
| 01/31/2026 | 10/31/2025 | 01/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -1,029.82% | -38.43% | -167.75% | ||
| Total Depreciation and Amortization | 0.00% | 25.00% | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 500,100.00% | -200.00% | -- | ||
| Change in Net Operating Assets | -323.97% | 106.67% | 221.95% | ||
| Cash from Operations | -28,855.00% | 88.60% | 44.97% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | 100.00% | -- | ||
| Cash from Investing | -- | 100.00% | -- | ||
| Total Debt Issued | -100.00% | -85.71% | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -100.00% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -100.00% | 2,931.37% | -- | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -114.27% | 993.03% | 363.02% | ||